The attention deficit hyperactivity disorder (ADHD) market is projected to grow at a compound annual growth rate (CAGR) of 8.5% during 2014 to 2024 to reach a value of $13.9bn by 2024, according to a new report by GlobalData.
Titled PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) – Global Drug Forecast and Market Analysis to 2024, the report anticipates that growing awareness of the disorder and improving drugs to address the condition will drive the ADHD market growth across seven major markets over the forecast period. The seven major markets include the US, France, Germany, Italy, Spain, the UK, and Japan.
The launch of certain promising late-stage pipeline drugs such as SPN-810 (molindone hydrochloride ER) by Supernus Pharmaceuticals and SHP-456 by Shire will be key drivers of growth in the ADHD market, according to Rachel Markwick, Ph.D, GlobalData’s analyst covering neurology and ophthalmology.
SPN-810 is targeted to treat symptoms such as impulsive aggression, while SHP-456, which is formulated to last for 16 hours, is a successor to Adderall XR, formulated to last for 12 hours.
Improvements such as covering more symptoms, reducing dosing frequency and introducing more convenient dosage forms are seen as further driving factors, reported GlobalData.
Although the current late-stage pipeline includes many stimulant formulations that offer the above-mentioned benefits, they are being targeted for approval in the US alone, said Markwick.
Markwick further commented: “Should companies seek approval for these products within the rest of the seven major markets, the unmet need of increased treatment options in these markets could be satisfied within the forecast period.”